HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

Shots: HUTCHMED has reported enrollment completion in P-II trial of fanregratinib to treat intrahepatic cholangiocarcinoma (IHCC) in pts with FGFR2 fusion or rearrangement; favorable trial results will support NMPA’s NDA submission The P-II trial of fanregratinib will assess ORR as 1EP whereas PFS, DCR, DoR, & OS as 2EPs in pts (n=87). Topline data…

ByRidhi RastogiMarch 7, 2025

Exclusive: David Esposito in an Illuminating Discussion with PharmaShots

Shots: Our recent Spotlight interview with David Esposito, CEO at ONL therapeutics became a major hit on the internet. We were moved by the overwhelming response from the netizens Here we have again, David Esposito in an engaging conversation with PharmaShots. David discusses in great length about the company’s lead candidate ONL1204, currently being evaluated…

ByAditya SinghMarch 12, 2024

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

In an interview with PharmaShots, Dr. Andrew Krivoshik, Senior Vice President and Oncology Therapeutic Area Head at Astellas, shared his views on the P-II FAST study result published in the journal Gastric Cancer and highlights the data published in Annals of Oncology. Shots: The data from P-II FAST study evaluating zolbetuximab + EOX in 1L patients with advanced gastric and…

BySenior EditorJuly 26, 2021

HUTCHMED Reports Enrollment Completion in P-II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma in China

Exclusive: David Esposito in an Illuminating Discussion with PharmaShots

PharmaShots Interview: Astellas’ Dr. Andrew Krivoshik Shares Insights on P-II FAST Study of Zolbetuximab

Contact US

FOLLOW US